Payment overview · 2025
General Payments
$602.07
32 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Keck Stahlman, DO
Allopathic & Osteopathic Physicians|Family Medicine · MESQUITE, TX · NPI 1679640957
Verified facts
What the public records show
CMS Open Payments records show Robert Keck Stahlman, DO received $602.07 in general payments during 2025 across 32 reported records.
PFIZER INC. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.38 | 23.8% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $106.39 | 17.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.21 | 16.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.70 | 11.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.29 | 11.5% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.43 | 7.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.95 | 6.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.13 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.59 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $602.07 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $106.39 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $76.39 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $76.39 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $76.39 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.29 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $66.99 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.80 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.94 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.52 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.43 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 170 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
170 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1183 | 335 |
| Carvedilol | Carvedilol | 653 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 570 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 166 |
| Metformin Hcl | Metformin Hcl | 548 | 157 |
| Pantoprazole Sodium | Pantoprazole Sodium | 472 | 137 |
| Gabapentin | Gabapentin | 379 | 119 |
| Celecoxib | Celecoxib | 357 | 98 |
| Losartan Potassium | Losartan Potassium | 332 | 94 |
| Lisinopril | Lisinopril | 320 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 84 |
| Furosemide | Furosemide | 297 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 81 |
| Montelukast Sodium | Montelukast Sodium | 263 | 72 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 256 | 71 |
| Glimepiride | Glimepiride | 229 | 66 |
| Trazodone Hcl | Trazodone Hcl | 224 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 207 | 30 |
| Omeprazole | Omeprazole | 206 | 63 |
| Allopurinol | Allopurinol | 202 | 54 |
| Meloxicam | Meloxicam | 202 | 48 |
| Ezetimibe | Ezetimibe | 199 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 195 | 56 |
| Potassium Chloride | Potassium Chloride | 193 | 64 |
| Tradjenta | Linagliptin | 186 | 36 |
| Eliquis | Apixaban | 170 | 40 |
| Ozempic | Semaglutide | 170 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 145 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 127 | 35 |
| Tramadol Hcl | Tramadol Hcl | 119 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 42 |
| Donepezil Hcl | Donepezil Hcl | 116 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 11 |
| Simvastatin | Simvastatin | 104 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 32 |
| Azithromycin | Azithromycin | 91 | 78 |
| Finasteride | Finasteride | 91 | 24 |
| Farxiga | Dapagliflozin Propanediol | 88 | 21 |
| Lovastatin | Lovastatin | 88 | 21 |
| Nifedipine Er | Nifedipine | 86 | 24 |
| Memantine Hcl | Memantine Hcl | 79 | 25 |
| Sertraline Hcl | Sertraline Hcl | 79 | 20 |
| Jardiance | Empagliflozin | 78 | 18 |
| Alprazolam | Alprazolam | 77 | 15 |
| Alendronate Sodium | Alendronate Sodium | 72 | 22 |
| Ciclopirox | Ciclopirox Olamine | 71 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 12 |
| Glipizide | Glipizide | 63 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 17 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 57 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 12 |
| Metformin Hcl Er | Metformin Hcl | 53 | 17 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Spironolactone | Spironolactone | 51 | 17 |
| Prednisone | Prednisone | 50 | 18 |
| Rybelsus | Semaglutide | 50 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 26 |
| Famotidine | Famotidine | 47 | 12 |
| Baclofen | Baclofen | 44 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | 15 |
| Naproxen | Naproxen | 44 | 11 |
| Pregabalin | Pregabalin | 44 | 13 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Valsartan | Valsartan | 43 | 11 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | 14 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Atenolol | Atenolol | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Fluconazole | Fluconazole | 34 | 14 |
| Doxepin Hcl | Doxepin Hcl | 33 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $602.07 · 32 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, JARDIANCE, Korlym, OFEV, OTEZLA, Ozempic, PREVNAR 20, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VYNDAQEL, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error